Beating its rivals, GSK nabs world-first approval for adult RSV vaccine Arexvy
Wednesday, the FDA blessed GSK’s RSV shot Arexvy for use in adults over 60. It becomes the world’s first RSV immunization for adults, beating out a closely watched program from Pfizer and another late-stage candidate from Moderna.